ArticleAnalytical and bioanalytical chemistry2026
Identification of semaglutide use through detection of U6 and U7 metabolites in human urine.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Semaglutide is a glucagon-like peptide 1 (GLP-1) agonist that has found widespread popularity as a weight loss product. Initially developed as a treatment for diabetes, the drug acts to stimulate the secretion of insulin, as well as suppress appetite by delaying gastric emptying and promoting satiety. By allowing users to moderate their weight, the drug may provide a competitive advantage to those individuals participating in sports that are regulated by weight classes, such as wrestling and boxing. Most current testing regimes for semaglutide rely on the use of blood samples. Here, a simple alternative LC-MS/MS test is presented that relies on urine, a much simpler matrix to obtain. The method is based on the detection of two unique semaglutide metabolites: U6 and U7. It was demonstrated to have an LOD of 50 pg/mL based on recovery from 2 mL of urine.
Indexed as
Identifiers
41364333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.